|1.||Bader, Michael: 7 articles (09/2012 - 11/2006)|
|2.||Lai, Josephine: 6 articles (01/2015 - 12/2006)|
|3.||Porreca, Frank: 6 articles (01/2015 - 12/2006)|
|4.||Kleinschnitz, Christoph: 5 articles (09/2012 - 05/2008)|
|5.||Stoll, Guido: 4 articles (03/2011 - 05/2008)|
|6.||Sirois, Pierre: 4 articles (01/2011 - 01/2003)|
|7.||Renné, Thomas: 4 articles (08/2010 - 05/2008)|
|8.||Lee, Yeon Sun: 3 articles (01/2015 - 05/2014)|
|9.||Meuth, Sven G: 3 articles (09/2012 - 08/2010)|
|10.||Bouillet, Laurence: 3 articles (01/2012 - 11/2009)|
01/01/2014 - "Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study."
01/01/2012 - "Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. "
08/01/2011 - "The clinical bottom line is there is promising evidence for the use of the bradykinin receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema."
09/01/2010 - "Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism."
08/05/2010 - "Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema."
11/01/2013 - "Role of the B1 bradykinin receptor and gC1qR/p33 in angioedema."
04/01/2013 - "There is limited experience using bradykinin receptor blockers and fresh frozen plasma (FFP) as a treatment modality for ACEI-induced angioedema. "
03/01/2015 - "The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED."
08/01/2015 - "The bradykinin receptor antagonist icatibant is proven to be effective in the treatment of acute attacks of hereditary angioedema, and has also been reported effective in the treatment of angioedema associated with ACE inhibitors. "
05/01/2014 - "Complement C1 inhibitor concentrate and bradykinin receptor antagonists, normally used to treat patients with hereditary angioedema, have shown good results when used in patients with bradykinin-mediated angioedema. "
|3.||Neuralgia (Stump Neuralgia)
02/01/2006 - "Antagonists of the B1 bradykinin receptor (B1R), encoded by the BDKRB1 gene, offer the promise of novel therapeutic agents for inflammatory and neuropathic pain. "
08/01/2004 - "Antagonists of the B1 bradykinin receptor (B1R) offer the promise of novel therapeutic agents for the treatment of inflammatory and neuropathic pain. "
10/01/2014 - "Ultimately our data support an increasing number of studies that suggest that blocking spinal bradykinin receptors may have a therapeutic potential in chronic pain states, here, in particular, in neuropathic pain. "
10/08/2001 - "Bradykinin receptors are believed to contribute to hyperalgesia under conditions of neuropathic pain. "
03/01/2009 - "Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care."
|4.||Asthma (Bronchial Asthma)
10/01/1998 - "Thus, bradykinin receptor antagonists may have therapeutic potential against asthma. "
09/01/2013 - "Expression of vascular remodelling markers in relation to bradykinin receptors in asthma and COPD."
04/01/2010 - "In the present study the effects of bradykinin receptor antagonists were investigated in a murine model of asthma using BALB/c mice immunized with ovalbumin/alum and challenged twice with aerosolized ovalbumin. "
|5.||Hypotension (Low Blood Pressure)
03/01/2001 - "Differences between peptide and nonpeptide B(2) bradykinin receptor antagonists in blocking bronchoconstriction and hypotension induced by bradykinin in anesthetized Guinea pigs."
01/01/1996 - "Infusion of the bradykinin receptor antagonist improved survival rates, hypotension, myocardial depression, and plasma lactate, suggesting that the bradykinin receptor antagonist inhibited the release of bradykinin and beta-endorphin, which contributed to the clinical improvement."
10/01/2010 - "Using both contaminated heparin products and the synthetically produced derivative, the authors have shown that the OSCS produces a dose-dependent hypotension in both pigs and rats and that the response in rats can be abrogated with bradyzide, a rodent-selective B(2) bradykinin receptor antagonist. "
|2.||beta-Endorphin (Endorphin, beta)
|4.||Nitric Oxide Synthase (NO Synthase)
|5.||Complement C1 (Complement 1)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|9.||2,5-dichloro-4-bromophenol (B 2)
|1.||Drug Therapy (Chemotherapy)